79340792 - BICYCLE ALPHA RADIONUCLIDE THERAPY

Information

• Trademark
• 79340792

• Source

• Serial Number

  79340792

• Registration Number

  7159642

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  February 25, 2022
  2 years ago

• Registration Date

  September 12, 2023
  8 months ago

• Transaction Date

  January 08, 2024
  5 months ago

• Status Date

  September 12, 2023
  8 months ago

• Published for Opposition Date

  June 27, 2023
  11 months ago

• Location Date

  September 12, 2023
  8 months ago

• Status Code

  700

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  LEASER, ANDREW C

• Attorney Docket Number

  571400

  Attorney Name

  Andrew D. Price & Paula E. Hopkins

  Law Office Assigned Location Code

  M80

• Owners

  • BicycleTx Limited

Case File Statements

• GS0051: Pharmaceuticals, for use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for use in the treatment and prevention of metabolic disease, urology and renal disease, in the cardiovascular field, in the field of hematology, for use in the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease
• GS0441: Medical services; medical testing for diagnostic or treatment purposes; healthcare services for the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for the treatment and prevention of metabolic disease, urology and renal disease, cardiovascular diseases, for the treatment and prevention of disease in the field of hematology, for the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; consultancy and information services relating to pharmaceuticals, namely, medical and pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in the field of respiratory disease; medical services in the field of cardiovascular disease; medical services in the field of metabolic disease; medical services in the field of the treatment and/or prevention of viral infections; medical services in the field of diagnostics and imaging; medical services in the field of renal disease; medical services in the field of gastrointestinal disease; medical services in the field of muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid
• D10000: "ALPHA RADIONUCLIDE THERAPY"
• GS0421: Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical and scientific research, namely, conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid

Case File Event Statements

• 1/8/2024 - 5 months ago

  27 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO

• 12/14/2023 - 5 months ago

  26 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS

• 12/14/2023 - 5 months ago

  25 - FINAL DISPOSITION PROCESSED Type: FIMP

• 12/12/2023 - 5 months ago

  24 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR

• 12/1/2023 - 6 months ago

  23 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP

• 9/12/2023 - 8 months ago

  22 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC

• 9/12/2023 - 8 months ago

  21 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 6/27/2023 - 11 months ago

  20 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 6/27/2023 - 11 months ago

  19 - PUBLISHED FOR OPPOSITION Type: PUBO

• 6/25/2023 - 11 months ago

  18 - NOTIFICATION PROCESSED BY IB Type: GPNX

• 6/7/2023 - a year ago

  17 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 6/7/2023 - a year ago

  16 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R

• 6/7/2023 - a year ago

  15 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 5/22/2023 - a year ago

  14 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 4/21/2023 - a year ago

  13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 4/20/2023 - a year ago

  12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 4/20/2023 - a year ago

  11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 11/21/2022 - a year ago

  10 - REFUSAL PROCESSED BY IB Type: RFNT

• 10/28/2022 - a year ago

  9 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 10/28/2022 - a year ago

  8 - REFUSAL PROCESSED BY MPU Type: RFRR

• 9/24/2022 - a year ago

  7 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH

• 9/11/2022 - a year ago

  6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 9/10/2022 - a year ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 9/7/2022 - a year ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 5/24/2022 - 2 years ago

  3 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 5/20/2022 - 2 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 5/19/2022 - 2 years ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR